OBJECTIVE: @entity1 with @entity304 ( @entity304 ) may have @entity528 . We studied the clinical features that may indicate @entity528 in @entity1 with @entity304 . METHODS: Forty-one @entity304 @entity1 were classified into normal and abnormal @entity8828 scan groups. Differences in 32 clinical features and drug withdrawal effects were studied. RESULTS: Twenty-eight @entity1 had normal (Group I) and 13 @entity1 had abnormal (Group II) scans. Eight @entity1 of Group I, but none of Group II, had taken @entity460 channel blockers (p = 0.040). Three @entity1 of Group I and six of Group II had @entity9905 (p = 0.018). After drug withdrawal, Group I showed greater improvement in Unified @entity191 Rating Scale total motor scores and subscores for @entity2845 and @entity400 than Group II. Only @entity9905 was an independent factor associated with abnormal scans, but it had suboptimal sensitivity. CONCLUSION: None of the clinical features were practical indicators of @entity528 in @entity1 with @entity304 .

Clinical Features Indicating @entity528 in XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity304 :: ('MESH:D010302', 'Disease') :: ['DIP', 'drug-induced parkinsonism'] @entity191 :: ('MESH:D010300', 'Disease') :: ["Parkinson's Disease"] @entity2845 :: ('MESH:D018476', 'Disease') :: ['bradykinesia'] @entity400 :: ('MESH:D014202', 'Disease') :: ['tremors'] @entity9905 :: ('MESH:C564321', 'Disease') :: ['hyposmia'] @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium'] @entity528 :: ('MESH:D009410', 'Disease') :: ['nigrostriatal dopaminergic degeneration'] @entity8828 :: ('MESH:C087552', 'Chemical') :: ['[(18)F] FP-CIT']
@entity304 :: (MESH:D010302,Disease) :: ['Drug-Induced Parkinsonism']
